Rapid Readouts: Initial Results of the Phase III BOSTON Study

Video

Related Videos
Francesco Di Meo, PhD
Jay Spiegel, MD
Related Content
He Huang, MD, PhD, of First Affiliated Hospital, Zhejiang University School of Medicine

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024
Article
Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022
Podcast
Saad Z. Usmani, MD, MBA, FACP, FASCO, of Memorial Sloan Kettering Cancer Center

Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

April 22nd 2024
Article
FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022
Podcast
David L. Porter, MD

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024
Article
Jack Gallagher, anesthetics trainee, simulation fellow, St George’s University Hospitals NHS Foundation Trust

Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence

April 15th 2024
Article